

the correlation between lipoprotein-associated phospholipase A2 and OxLDL

by Prof. Dr. Muh. Nasrum Massi, Ph.d

Submission date: 01-Dec-2021 01:53PM (UTC+0700)

Submission ID: 1717204913

File name: the_correlation_between_L.pdf (1,004.61K)

Word count: 132

Character count: 633

RESEARCH ARTICLE

The Correlation between Lipoprotein-Associated Phospholipase A₂ and Atherosclerosis (ox-LDL) in Centrally Obese Men

Priscilla Dian Ari^{1,2*}, Ellis Susanti^{2,4}, Ilham Jaya Patellongi³,

¹Prodia Clinical Laboratory, Jl. A. Yani, Kompleks Cenderawasih Trade Center, Blok A-6, Samarinda, Indonesia

²Post Graduate Program in Clinical Biochemistry, Hasanuddin University, Jl. Perintis Kemerdekaan Km.10. Makassar, Indonesia

³Faculty of Medicine, Hasanuddin University, Jl. Perintis Kemerdekaan Km.10. Makassar, Indonesia

⁴Prodia Clinical Laboratory, Jl. Kramat Raya 150, Jakarta, Indonesia

*Correspondence: priscilla.dian@prodia.co.id

Abstract

BACKGROUND: Obesity is closely associated with atherosclerosis. Obesity and atherosclerosis are closely associated with inflammatory disease. Atherosclerosis constitutes a multifactorial disorder affecting the arterial wall, which is initiated by dyslipidemia and exacerbated by inflammation. Plasma levels of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) and oxidized low density lipoprotein (ox-LDL) have been identified as risk factors for cardiovascular disease. Lp-PLA₂ is the sole enzyme responsible for the hydrolysis of oxidized phospholipids (oxPL) on LDL particles in atherosclerosis plaque. Plasma level of oxLDL is associated with inflammation and plays an important role in the development of atherosclerosis. The aim of this study was to assess the correlation between Lp-PLA₂ and atherosclerosis (oxLDL) in centrally obese men.

METHODS: This was a cross-sectional study involving 71 men with central obesity with waist circumference > 90 cm, aged 30-60 years old. Lp-PLA₂ measurement was done by sandwich enzyme immunoassay. oxLDL measurement was done by ELISA method.

Abstrak

LATAR BELAKANG: Obesitas terkait erat dengan aterosklerosis. Obesitas dan aterosklerosis terkait erat dengan inflamasi. Aterosklerosis merupakan gangguan multifaktorial yang mempengaruhi dinding arterial, yang diinisiasi oleh dislipidemia dan diperkuat oleh adanya inflamasi. *Lipoprotein-associated phospholipase A₂ (Lp-PLA₂)* dan *oxidized low density lipoprotein (ox-LDL)* telah diidentifikasi merupakan faktor risiko kardiovaskular. Lp-PLA₂ merupakan enzim yang terlibat dalam hidrolisis oxidized phospholipids (oxPL) pada partikel LDL dalam plak aterosklerosis. Konsentrasi oxLDL terkait dengan inflamasi dan berperan penting dalam perkembangan aterosklerosis. Studi ini bertujuan untuk menilai korelasi antara Lp-PLA₂ dan aterosklerosis (oxLDL) pada pria obesitas sentral.

METODA: Studi ini menggunakan metoda *cross-sectional* yang melibatkan 71 pria dengan obesitas sentral yang ditandai dengan lingkaran perut/*waist circumference* (WC) > 90 cm, berusia 30-60 tahun. Konsentrasi Lp-PLA₂ ditentukan menggunakan metoda *sandwich enzyme immunoassay*. Penentuan konsentrasi oxLDL dilakukan menggunakan metoda ELISA.

RESULTS: Results of this study showed that central obesity correlated positively with oxLDL ($r = 0.258^*$; $p = 0.040$) and Lp-PLA₂ > 422 ng/mL correlated positively with oxLDL ($r = 0.331^*$; $p = 0.042$).

CONCLUSIONS: We conclude that there is a correlation of Lp-PLA₂ with atherosclerosis (oxLDL) in men with central obesity.

KEYWORDS: obesity, Lp-PLA₂, oxLDL, atherosclerosis

Indones Biomed J 2012; 4 (2): 101–106

RESULTS: Hasil studi menunjukkan bahwa obesitas sentral berhubungan positif dengan oxLDL ($r = 0,258^*$; $p = 0,040$) dan Lp-PLA₂ > 422 ng/mL berkorelasi positif dengan oxLDL ($r = 0,331^*$; $p = 0,042$).

KESIMPULAN: Hasil studi ini menyimpulkan bahwa terdapat korelasi antara Lp-PLA₂ dengan aterosklerosis (oxLDL) pada pria dengan obesitas sentral.

KATAKUNCI: obesitas, Lp-PLA₂, oxLDL, aterosklerosis

Indones Biomed J 2012; 4 (2): 101–106

Introduction

One of the most important recent developments in the study on obesity is the emergence of the concept that obesity is characterized by chronic mild inflammation – paralleling the situation with other diseases. The basis for this view is that the circulating level of several cytokines and acute phase proteins associated with inflammation is increased in obese individuals (1). Previous studies have demonstrated that enlargement of adipocytes is associated with substantial changes in metabolic functions, *e.g.* in lipid metabolism (2). It has been hypothesized that such alteration may contribute to the health-related risks of obesity. Obesity is linked to a variety of metabolic disorders such as insulin resistance and atherosclerosis. Abnormal regulation of fat production– derived secretory factors, adipocytokines, is partly responsible for obesity – linked metabolic disorders (3).

Lipoprotein-associated phospholipase A₂ (Lp-PLA₂), also known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A₂ enzyme. In the blood it travels mainly with small-dense low density lipoprotein (sdLDL). It is an enzyme produced by inflammatory cells and hydrolyzes oxidized phospholipids in LDL. Lp-PLA₂ is involved in the development of atherosclerosis. Hydrolysis of phospholipids that is associated with lipoprotein particles by the phospholipase A₂ family of enzymes leads to modulation of lipoprotein particle phospholipid content and size as well as production of both pro- and antiinflammatory intermediates, all of which may serve as a basis for involvement of these enzymes in the

development of atherosclerosis. In human atherosclerotic lesions, two main sources of Lp-PLA₂ can be identified, including that which is brought into the intima bound to LDL (from the circulation), and that which is synthesized *de novo* by plaque inflammatory cells (macrophages, T cells, mast cells). It is used as a marker for cardiac disease. A meta-analysis involving a total of 79.036 participants in 32 prospective studies showed that Lp-PLA₂ levels are positively correlated with increased risk of developing coronary heart disease and stroke (4). Lipid-lowering agents, particularly statins, lower Lp-PLA₂ mass and activity; therefore, Lp-PLA₂ may represent an important target of lipid-lowering therapy for reducing the inflammatory nature of atherosclerosis and plaque vulnerability (16). Lp-PLA₂ results are categorized into three progressive levels of cardiovascular risk: low < 310 ng/mL; moderate 310-422 ng/mL; high > 422 ng/mL (17).

The mechanisms underlying the pathogenesis of atherosclerosis are complex and affected by interaction among several biological pathways, including those of inflammation, metabolic disorder, and oxidative stress (5). The process of inflammation has been shown pathohistologically in advanced atherosclerotic plaques. Inflammation is mediated by the increasing quantities of proinflammatory cytokines. An early event in the progression of the disease is accumulation of LDL that may become oxidized. LDL can be oxidized enzymatically. With further oxidization, recognition by scavenger receptors occurs, leading to foam cell formation (6).

Oxidative modification of LDL is regarded as a key step in the formation of atherosclerosis. OxLDL involved in atherosclerogenic steps such as endothelial dysfunction, migration of macrophage and smooth muscle

cells, and release of inflammatory cytokines, induces oxidative stress and incorporated with macrophage transformation into foam cells and atherosclerotic plaque formation (7). Growing evidence indicates a relationship between circulating oxLDL and pathogenic processes of cardiovascular disease. Thus, circulating oxLDL has been established as a biomarker of atherosclerosis (8). The presence of circulating antibodies against oxLDL suggests its availability as an antigen outside the vascular system. Cholesterol crystals, detected not only in necrotic cores but also in the subendothelial areas in early atherosclerotic settings, trigger inflammasome activation, leading to interleukin-1 β secretion. Their possible source may be the circulation (6).

Methods

SUBJECTS

This study was observational with a cross-sectional design done on a group of centrally obese men (n=71). The subjects' ages were between 30-60 years; they had central obesity with waist circumference \geq 90 cm. Before commencement of the study, all subjects signed an informed consent. None of the subjects had acute inflammation (hsCRP \geq 10 mg/L), kidney disorder, and nor consuming anti-inflammatory drug. All subjects underwent standardized interviews and physical and laboratory examinations.

ASSAY OF BIOCHEMICAL MARKERS

The plasma levels of Lp-PLA₂ were measured using two highly specific monoclonal antibodies for direct measurement of concentration. The PLACTM Test Regent Kit (diaDexus Inc. manufacturer, South San Francisco), a turbidimetric immunoassay, was used. oxLDL in EDTA plasma/serum/plasma heparin (oxLDL) was measured by sandwich /capture ELISA based on the mouse monoclonal antibody 4E6 (Merckodia, Uppsala, Sweden).

STATISTICAL ANALYSIS

Statistical analysis was done by SPSS for Windows v 17 with a level at $p < 0.05$. The correlations between biomarkers were assessed by Pearson or Spearman's rho correlation test.

Results

Table 1 provides information on the general and biochemical characteristics of the study subjects. In general, the population characteristics of the subjects were in compliance with the inclusion and exclusion criteria. On each subject's characteristics we did normal distribution test (Kolmogorov Smirnov Test).

Table 1. General Characteristics of Subjects

Variable	Min	Max	Mean \pm SD	p
Age (year)	30.00	60.00	43.90 \pm 8.69	0.165
WC (cm)	90.00	125.00	97.45 \pm 7.26	0.016
hsCRP (mg/L)	0.29	8.53	1.84 \pm 1.59	0.935
Creatinine (mg/dL)	0.60	1.20	0.90 \pm 0.12	0.855
eGFR (ng/mL)	64.00	132.00	91.00 \pm 5.15	0.029
Lp-PLA ₂ (ng/mL)	18.00	682.00	423.60 \pm 4.35	0.082
oxLDL (U/L)	53.00	245.00	98.70 \pm 2.70	0.271

WC = Waist Circumference, hsCRP = high sensitivity C – Reactive Protein; eGFR = estimate glomerulus filtration rate.

Pearson or Spearman's correlations test was performed to assess correlation between parameters. The result showed positive correlation of oxLDL with central obesity based on waist circumference 90-110 cm ($p=0.040$), hsCRP with oxLDL also showed linear correlation ($p=0.047$). This suggests that an increased waist circumference in inflammatory conditions contribute to the pathogenesis of atherosclerosis (Table 2).

The statistical analyses in this study showed a potential correlation of increased Lp-PLA2 > 422 ng/mL with atherosclerosis (oxLDL) in the group of centrally obese men. This finding indicated that high concentration of Lp-PLA2 contributes to the pathogenesis of atherosclerosis. This result is presented in a scatter graph, as shown in Figure 1.

Table 2. Correlation between WC, hs-CRP with oxLDL in Centrally Obese Men

Variable	oxLDL	
	r	p
WC	0.258*	0.040
hsCRP	0.248*	0.047




Figure 1. Correlation of Lp-PLA2 with oxLDL.

Discussions

Results of this study showed relationship between central obesity and inflammatory condition with the pathogenesis of atherosclerosis as shown by the linear analysis results ($p < 0.05$). In central obesity, adipocytes are stimulated to synthesize proinflammatory cytokines such as TNF- α and Interleukin-6. These cytokines constitute the main regulators of CRP synthesis. The level of hsCRP can be regarded as an atherosclerosis predictor. Obesity is associated with chronic low-grade inflammatory condition resulting from the adipose tissues. Inflammation triggered by obesity may accelerate the process of atherosclerosis (9).

In this study we found no correlation of hsCRP with Lp-PLA₂. It is conceivable that these two biomarkers relate to different atherogenesis mechanisms. Jenny *et al.* examined the influence of CRP on Lp-PLA₂ associations with cardiac events. In all of the models tested, there were no statistically significant multiplicative interactions of CRP with Lp-PLA₂ mass or activity. Addition of CRP (by cutpoints, < 1 mg/L, $1-3$ mg/L, ≥ 3 mg/L) to the multivariable models for Lp-PLA₂ mass or activity did not appreciably alter associations of these factors with CVD events. CRP and Lp-PLA₂ were independent predictors of events and there was a significant additive effect when the biomarkers were combined (10).

In this study we found that Lp-PLA₂ > 422 ng/mL had a linear correlation with oxLDL ($p = 0.042$). This finding supports the previous studies that showed Lp-PLA₂ was related to stroke occurrence (11). Other study found Lp-PLA₂ to be correlated with the increased incidence of heart attack and other death-causing vascular diseases (12). Lp-PLA₂ hydrolyzes oxidized phospholipid in oxLDL that results in lysophosphatylcholine and oxidized fatty acid, which are proinflammatory substance and act to accelerate atherosclerosis process (13).

The most abundant oxPL in oxLDL is oxidized phosphatidylcholine (oxPC), which typically carries a truncated sn-2 acyl chain of nine carbons. oxPC is a specific substrate for the enzyme Lp-PLA₂, which release an oxidized short-chain fatty acid and lysophosphatidylcholine (LysoPC). LysoPC is a highly atherogenic lipid which induces multiple deleterious processes in the atherosclerotic plaque (13).

Perssons *et al.* determined the relationship between Lp-PLA₂, the metabolic syndrome and incident CVD in 4480 individuals. Lp-PLA₂ mass was significantly higher in the individuals with Mets. The combination of

both MetS and increased Lp-PLA₂ could, therefore be a prognostic marker for high-risk individuals (14).

Lp-PLA₂ is secreted predominantly by the macrophage. Its expression and secretion significantly increase during differentiation of human monocytes into macrophages as well as dramatically increase during activation of macrophages in the atherosclerotic lesion. It is thought that in plasma, Lp-PLA₂ is circulating bound to LDL (80%) and HDL (20%). Inhibition of Lp-PLA₂ activity will abolish the inflammatory response of the cells (15).

Vickers *et al.* observed that Lp-PLA₂ was significantly more abundant in atherosclerotic lesions than in normal tissue ($p < 0.05$). This might explain why no correlation is found between low concentration of Lp-PLA₂ (> 422 ng/mL) and oxLDL in centrally obese men. Plasma Lp-PLA₂ levels represent risk related to the total burden of vascular inflammation and not just the burden arising from particular atheroma. Likewise, the plasma Lp-PLA₂ level reflects the contributing factors deriving from a single lesion, but mainly from multiple atherosclerotic sites (13).

Conclusion

This study showed a strong correlation between Lp-PLA₂ > 422 ng/mL and oxLDL in centrally obese men ($r = 0.331^*$; $p = 0.042$).

Acknowledgement:

We would like to thank the Prodia Education and Research Institute, Research Support Department of Prodia Clinical Laboratory, Prodia Clinical Laboratory – Makassar, and Prodia Clinical Laboratory – Bandung, for their invaluable supports to this research.

References:

1. Trayhurn P. Adipocyte Biology. *Obes Rev* 2007; 8 (suppl. 1): 41-4.
2. Engfeldt P, Arner P. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. *Horm Metab Res Suppl.* 1988; 19: 26-9.
3. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, *et al.* Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. *Diabetes* 2007; 56: 901-11
4. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S *et al.* Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet* 2010; 375: 1536-44.

5. Ishigaki Y, Oka Y, Katagiri H. Circulating oxidized LDL: a biomarker and a pathogenic factor. *Curr Opin Lipidol* 2009; 20: 363-9
6. Grundtman C, Wick G. The autoimmune concept of atherosclerosis. *Curr Opin Lipidol* 2011; 22: 327-34
7. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. *Atherosclerosis* 2006; 185: 219-26
8. Tsimikas S. Oxidized low-density lipoprotein biomarkers in atherosclerosis. *Curr Atheroscler Rep* 2006; 8: 55-61
9. Lyon CJ, Law RE, Hsueh WA. Minireview ; Adiposity, Inflammation, and Atherogenesis. *Endocrinology*. 2003;144: 2195-200
10. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, *et al.* Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. *Atherosclerosis* 2010; 209: 528-32
11. Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. *Clin Chem* 2010; 56: 21-33
12. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Recurrent Coronary Events in Postinfarction Patients. *Clin Chem* 2006; 52: 1331-8.
13. Vickers KC, Maguire CT, Wolfert R, Burns AR, Reardon M, Geis R *et al.* Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis. *J Lipid Res* 2009; 50: 1735-42
14. Wraahle KWJ, Heys SD. Atherosclerosis : cell biology and lipoprotein. *Curr Opin Lipidol* 2008; 19: 435-7
15. Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, *et al.* The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study". *J. Am. Coll. Cardiol.* 2008; 51: 1632-41
16. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, *et al.* Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. *Circulation* 2006; 113: 1745-52.
17. Ballantyne CM, Hoogeveen RC, Bang H, *et al.* Lipoprotein-associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. *Arch Intern Med* 2005; 165: 2479-84.

the correlation between lipoprotein-associated phospholipase A2 and OxLDL

ORIGINALITY REPORT

0%

SIMILARITY INDEX

0%

INTERNET SOURCES

0%

PUBLICATIONS

0%

STUDENT PAPERS

PRIMARY SOURCES

Exclude quotes On

Exclude bibliography On

Exclude matches < 5 words